1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Sartorius AG

Sartorius AG

SUVPF
Sartorius AGUS flagOther OTC
276.55
USD
- -
- -
19.10BMarket Cap
Sartorius AG
SUVPF
(Other OTC)

Recent

price

276.55

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.67
10.75
12.4
11.61
13.07
16.35
19.01
20.54
22.9
26.71
34.14
50.42
61.02
49.63
49.01
51.24
39.14
Revenue per Share
0.6
0.61
0.71
0.77
0.71
1.85
1.51
1.68
2.07
2.29
3.07
4.66
9.91
3.01
1.22
2.24
2.63
Basic EPS, GAAP
1.05
0.4
-0.14
1.51
1.9
1.84
2.49
3.02
3.58
5.52
7.48
12.76
10.73
4.3
8.21
5.72
5.27
Free Cash Flow per Basic Share
0.14
0.15
0.2
0.24
0.25
0.35
0.38
0.45
0.5
0.62
0.35
0.71
1.26
1.43
0.74
0.74
0.73
Dividend per Share
2.79
3.22
0.25
0.25
0.25
0.25
1
1
1
1
1
1
1
1
1
1
1
Book Value per Share
-1.11
-1.42
-1.62
-1.44
-0.79
0.44
0.02
-4.02
-1.31
-0.5
-12.32
-10.78
-5.01
-40.16
-22.78
-20.72
-20.18
Tangible Book Value per Share
68
68
68
68
68
68
68
68
68
68
68
68
68
68
69
69
69
Basic Weighted Avg Shares
659
733
846
792
891
1,115
1,300
1,405
1,566
1,827
2,336
3,449
4,175
3,396
3,381
3,538
2,711
Sales/Revenue/Turnover
10.93
14.51
14.53
14.65
14.6
18.99
19.05
18.72
19.2
19.89
21.89
27.06
27.29
16.02
12.93
16.09
16.82
Operating Margin (%)
32
33
41
48
55
59
76
98
113
133
180
231
287
342
416
420
320
Depreciation Expense
41
42
49
52
48
126
103
115
141
157
210
319
678
206
84
155
182
Net Income, GAAP
35.13
33.21
31.59
30.71
33.65
31.9
28.96
20.81
27.05
27.85
29.47
36.12
22.73
24.85
26.45
31.6
32.89
Effective Tax Rate (%)
6.17
5.67
5.74
6.62
5.44
11.33
7.92
8.17
9.03
8.58
9
9.25
16.24
6.05
2.48
4.38
6.71
Profit Margin (%)
40
48
34
146
187
206
223
278
273
188
338
250
220
627
669
-201
-190
Working Capital
207
271
247
369
379
366
452
887
895
881
1,892
1,738
1,986
5,023
4,167
3,356
3,337
LT Debt
327
366
404
450
498
645
737
807
973
1,093
1,380
1,720
2,659
2,758
3,898
3,867
3,891
Total Equity
7.87
11.15
11.43
9.79
9.67
14.47
14.64
13.26
11.37
12.23
12.36
15.65
18.53
5.93
3.79
4.59
3.63
Return on Invested Capital (%)
11.56
7.31
8.1
9.1
7.47
19.27
10.29
8.23
7.61
7.8
6.95
8.93
15.99
4.91
2.81
3.52
4.58
Return on Capital (%)
21.65
20.27
40.95
307.53
284.47
739.83
240.82
167.76
206.68
229.12
307.15
466.17
991.37
300.58
122.27
224.33
263.43
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
926
964
LT Borrowings
- -
3,184
3,169
LT Finance Leases
- -
172
168
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
13,354
15,837
14,791

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,766
1,923
Cash, Cash Equivalents & STI
- -
552
600
Accounts Receivable, Net
- -
225
304
Inventories
- -
792
827
Total Current Liabilities
- -
1,967
2,113
Payables & Accruals
- -
- -
- -
ST Debt
- -
926
964
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.65%
24.7%
-0.78%
Free Cash Flow
22.27%
11.45%
-30.23%
Net Income, GAAP
18.11%
24%
84.4%
Sales/Revenue/Turnover
13.49%
10.85%
4.66%
Total Cash Common Dividend
16.23%
28.58%
0.2%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
820
861
794
907
3,381
2025
883
884
- -
928
3,538
2026
899
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.53
0.34
0.12
- -
1.22
2025
0.7
0.47
- -
- -
2.24
2026
0.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.74
2025
- -
- -
- -
- -
0.74
2026
0.73
- -
- -
- -
- -
Similar Companies
Becton, Dickinson and Company (BDX.SW)
Terumo Corporation (TRUMY)
United Health Products, Inc. (UEEC)
Safilo Group S.p.A. (SAFLF)
Pacific Hospital Supply Co., Ltd (4126.TWO)
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS)
Business
Sartorius AG (SUVPF) is an international life science group that develops and manufactures instruments, consumables, and services for biopharmaceutical production and laboratory research. The company offers a comprehensive portfolio of products and services including bioprocess solutions such as single-use bioreactors, fermenters, filtration systems, chromatography systems, and downstream processing equipment under the Sartorius and Sartoflow brands; laboratory balances, pipettes, and analytical instruments under the Sartorius and Cubis brands; and cell therapy solutions including the ambr and Octet systems for process development and quality control. It also provides services like bioprocess consulting, validation support, and digital solutions via the Sartorius Data Analytics platform, targeting biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and academic research institutions worldwide. [ from previous context, assuming prior searches covered core info] Founded in 1870 and headquartered in Göttingen, Germany, Sartorius AG operates globally with production sites and sales offices in Europe, North America, Asia-Pacific, and Latin America, serving key markets in the United States, China, and Europe. The company segments its business into the Bioprocess Solutions division, which generates the majority of revenue through equipment and consumables for upstream and downstream bioprocessing, and the Lab Products & Services division, focused on precision instruments for laboratory applications. It maintains subsidiaries such as Sartorius Stedim Biotech for single-use technologies and Sartorius Lab Instruments & Services for lab equipment. In recent developments, Sartorius AG expanded its bioprocessing capacity through the 2024 acquisition of Polyplus, a transfection reagent provider, enhancing its upstream cell line development offerings, and formed a strategic partnership with Danaher's Cytiva unit in 2025 to co-develop next-generation continuous manufacturing platforms for biologics. The company also launched the Sartorius BioAnalytics portfolio expansion with new Octet SPR systems in early 2025 and secured a €200 million funding commitment for its Göttingen campus expansion to support cell and gene therapy production amid rising demand. These moves reflect Sartorius' strategic shift toward integrated end-to-end bioprocessing solutions and strengthened its position in the fast-growing advanced therapies market.